PLX   $1.69  1.81% Market Closed After Close 1.6924 0.14%

Protalix Biotherapeutics Inc
Last Events:

2023-08-09 Signal in RSI changed from bearish recovery to bullish. RSI indicator is in the upper part of the neutral territory and it heading north. These factors indicate that positive dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-09 Signal in EMA20 changed from bearish reversal to bullish reversal. The price is trying to cross up the moving average line If the intersection will be successful, then an upside trend can be formed.

2023-08-06 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-04 Signal in Stochastic changed from bullish weakening to bearish reversal. The stochastic indicator is in the upper part of the neutral territory and left the overbought territory. These factors indicate that perhaps the upside trend is coming to an end price will probably head south Last signal: exit from the overbought zone.

2023-08-04 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-08-03 Signal in Stochastic changed from bullish to bullish weakening. The stochastic indicator is in overbought territory and it heading south. These factors indicate that perhaps the upside trend is coming to an end. Last signal: main and signal line crossing.

2023-07-30 Signal in MACD changed from bearish weakening to bullish reversal. Oscillator MACD is in the negative territory it crossed the signal line from the bottom and grows. These factors mean that the market confirms the end of the downward trend. Last signal: main and signal line crossing.

2023-07-30 Signal in RSI changed from bullish reversal to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.


Current temperature: 0.00
ST: 0, Cor:

50-50 Year Forecast
Low with % probability:
Target: 1.46
High with % probability:
Analyst Recommendations:
Number of estimates 1
Target Price Mean 14.00
Mean unverified/preliminary 14.00 / 14.00
Target Price Low / High 14.00 / 14.00
Median / STD DEV 14.00 / 0.00
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy ActivelyBuy None
rsi ActivelyBuy ActivelyBuy None
macd None None None
stoch None None None
ma20 Buy ActivelyBuy None
ma50 None None None
ma100 Buy ActivelyBuy None
Candlestick PatternNov. 15, 2024 Bearish Harami - consists of an unusually large white body followed by a small black body contained within. Large white body It is considered as a bearish pattern when preceded by an uptrend.
ISIN US74365A3095
ceo Mr. Dror Bashan
Website https://www.protalix.com
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.